Emerging role of anti-IL23 in the treatment of psoriasis : When humanized is very promising
© 2020 Wiley Periodicals LLC..
Risankizumab is a novel anti-interleukin 23 humanized antibody developed to treat severe psoriasis. In this paper, we analyze the key information about this new drug and the results of phase 3 clinical trials already present in literature in order measure its safety and effectiveness in every day practice. Risankizumab seems to be one of the best performing drugs in the treatment of psoriasis, with a good safety profile and a dosage regimen less frequent than all other biologic agents, although head-to-head randomized clinical trials with other anti-interleukin treatments will be necessary in order to confirm these preliminary results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Dermatologic therapy - 33(2020), 6 vom: 15. Nov., Seite e14504 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dattola, Annunziata [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-IL23 |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dth.14504 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317097873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317097873 | ||
| 003 | DE-627 | ||
| 005 | 20231225162522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dth.14504 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM317097873 | ||
| 035 | |a (NLM)33141505 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dattola, Annunziata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging role of anti-IL23 in the treatment of psoriasis |b When humanized is very promising |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 14.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals LLC. | ||
| 520 | |a Risankizumab is a novel anti-interleukin 23 humanized antibody developed to treat severe psoriasis. In this paper, we analyze the key information about this new drug and the results of phase 3 clinical trials already present in literature in order measure its safety and effectiveness in every day practice. Risankizumab seems to be one of the best performing drugs in the treatment of psoriasis, with a good safety profile and a dosage regimen less frequent than all other biologic agents, although head-to-head randomized clinical trials with other anti-interleukin treatments will be necessary in order to confirm these preliminary results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Risankizumab | |
| 650 | 4 | |a anti-IL23 | |
| 650 | 4 | |a biologic therapy | |
| 650 | 4 | |a psoriasis | |
| 650 | 7 | |a Interleukin-23 |2 NLM | |
| 700 | 1 | |a Silvestri, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Tamburi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Amoruso, Giuseppe F |e verfasserin |4 aut | |
| 700 | 1 | |a Bennardo, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Nisticò, Steven P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 33(2020), 6 vom: 15. Nov., Seite e14504 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:6 |g day:15 |g month:11 |g pages:e14504 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.14504 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 6 |b 15 |c 11 |h e14504 | ||